238 related articles for article (PubMed ID: 31883847)
1. Allergen-specific IgG
Hoof I; Schulten V; Layhadi JA; Stranzl T; Christensen LH; Herrera de la Mata S; Seumois G; Vijayanand P; Lundegaard C; Niss K; Lund A; Ahrenfeldt J; Holm J; Steveling E; Sharif H; Durham SR; Peters B; Shamji MH; Andersen PS
J Allergy Clin Immunol; 2020 Jul; 146(1):180-191. PubMed ID: 31883847
[TBL] [Abstract][Full Text] [Related]
2. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells.
Scadding GW; Shamji MH; Jacobson MR; Lee DI; Wilson D; Lima MT; Pitkin L; Pilette C; Nouri-Aria K; Durham SR
Clin Exp Allergy; 2010 Apr; 40(4):598-606. PubMed ID: 20184605
[TBL] [Abstract][Full Text] [Related]
3. IgE+ B cells are scarce, but allergen-specific B cells with a memory phenotype circulate in patients with allergic rhinitis.
Wong KJ; Timbrell V; Xi Y; Upham JW; Collins AM; Davies JM
Allergy; 2015 Apr; 70(4):420-8. PubMed ID: 25556717
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneity of antibody responses among clinical responders during grass pollen sublingual immunotherapy.
Baron-Bodo V; Horiot S; Lautrette A; Chabre H; Drucbert AS; Danzé PM; Sénéchal H; Peltre G; Galvain S; Zeldin RK; Horak F; Moingeon P
Clin Exp Allergy; 2013 Dec; 43(12):1362-73. PubMed ID: 24261946
[TBL] [Abstract][Full Text] [Related]
5. Nasal allergen-neutralizing IgG
Shamji MH; Kappen J; Abubakar-Waziri H; Zhang J; Steveling E; Watchman S; Kouser L; Eifan A; Switzer A; Varricchi G; Marone G; Couto-Francisco NC; Calderon M; Durham SR
J Allergy Clin Immunol; 2019 Mar; 143(3):1067-1076. PubMed ID: 30445057
[TBL] [Abstract][Full Text] [Related]
6. Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG
Eckl-Dorna J; Weber M; Stanek V; Linhart B; Ristl R; Waltl EE; Villazala-Merino S; Hummel A; Focke-Tejkl M; Froeschel R; Neubauer A; Henning R; Perkmann T; Valenta R; Niederberger V
EBioMedicine; 2019 Dec; 50():421-432. PubMed ID: 31786130
[TBL] [Abstract][Full Text] [Related]
7. Allergen specificity of IgG(4)-expressing B cells in patients with grass pollen allergy undergoing immunotherapy.
James LK; Bowen H; Calvert RA; Dodev TS; Shamji MH; Beavil AJ; McDonnell JM; Durham SR; Gould HJ
J Allergy Clin Immunol; 2012 Sep; 130(3):663-670.e3. PubMed ID: 22583928
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.
Schmid JM; Würtzen PA; Dahl R; Hoffmann HJ
J Allergy Clin Immunol; 2016 Feb; 137(2):562-70. PubMed ID: 26141262
[TBL] [Abstract][Full Text] [Related]
9. Intradermal grass pollen immunotherapy increases T
Slovick A; Douiri A; Muir R; Guerra A; Tsioulos K; Hay E; Lam EPS; Kelly J; Peacock JL; Ying S; Shamji MH; Cousins DJ; Durham SR; Till SJ
J Allergy Clin Immunol; 2017 Jun; 139(6):1830-1839.e13. PubMed ID: 27773851
[TBL] [Abstract][Full Text] [Related]
10. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
[TBL] [Abstract][Full Text] [Related]
11. VH gene usage in immunoglobulin E responses of seasonal rhinitis patients allergic to grass pollen is oligoclonal and antigen driven.
Davies JM; O'Hehir RE
Clin Exp Allergy; 2004 Mar; 34(3):429-36. PubMed ID: 15005737
[TBL] [Abstract][Full Text] [Related]
12. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity.
Nouri-Aria KT; Wachholz PA; Francis JN; Jacobson MR; Walker SM; Wilcock LK; Staple SQ; Aalberse RC; Till SJ; Durham SR
J Immunol; 2004 Mar; 172(5):3252-9. PubMed ID: 14978133
[TBL] [Abstract][Full Text] [Related]
13. Recombinant monoclonal human immunoglobulin E to investigate the allergenic activity of major grass pollen allergen Phl p 5.
Madritsch C; Flicker S; Scheiblhofer S; Zafred D; Pavkov-Keller T; Thalhamer J; Keller W; Valenta R
Clin Exp Allergy; 2011 Feb; 41(2):270-80. PubMed ID: 21143538
[TBL] [Abstract][Full Text] [Related]
14. Distinct Contributory Factors Determine Basophil-Allergen Sensitivity in Grass Pollen Rhinitis and in Anaphylactic Wasp Venom Allergy.
Korošec P; Šilar M; Kopač P; Eržen R; Zidarn M; Košnik M
Int Arch Allergy Immunol; 2016; 171(2):89-101. PubMed ID: 27907922
[TBL] [Abstract][Full Text] [Related]
15. Influence of seasonal exposure to grass pollen on local and peripheral blood IgE repertoires in patients with allergic rhinitis.
Wu YC; James LK; Vander Heiden JA; Uduman M; Durham SR; Kleinstein SH; Kipling D; Gould HJ
J Allergy Clin Immunol; 2014 Sep; 134(3):604-12. PubMed ID: 25171866
[TBL] [Abstract][Full Text] [Related]
16. Synchronous immune alterations mirror clinical response during allergen immunotherapy.
Renand A; Shamji MH; Harris KM; Qin T; Wambre E; Scadding GW; Wurtzen PA; Till SJ; Togias A; Nepom GT; Kwok WW; Durham SR
J Allergy Clin Immunol; 2018 May; 141(5):1750-1760.e1. PubMed ID: 29128670
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy.
Wachholz PA; Soni NK; Till SJ; Durham SR
J Allergy Clin Immunol; 2003 Nov; 112(5):915-22. PubMed ID: 14610480
[TBL] [Abstract][Full Text] [Related]
18. RNA sequencing of single allergen-specific memory B cells after grass pollen immunotherapy: Two unique cell fates and CD29 as a biomarker for treatment effect.
McKenzie CI; Varese N; Aui PM; Reinwald S; Wines BD; Hogarth PM; Thien F; Hew M; Rolland JM; O'Hehir RE; van Zelm MC
Allergy; 2023 Mar; 78(3):822-835. PubMed ID: 36153670
[TBL] [Abstract][Full Text] [Related]
19. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study.
Bufe A; Ziegler-Kirbach E; Stoeckmann E; Heidemann P; Gehlhar K; Holland-Letz T; Braun W
Allergy; 2004 May; 59(5):498-504. PubMed ID: 15080830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
